Lorazepam attenuates the behavioral effects of dizocilpine

Pharmacology Biochemistry and Behavior

Volumn 62, Issue 1, 1999, Pages 103-110

  Fahey, Jeanne M ^a   Pritchard, Gary A ^a   Pratt, John S ^a   Shader, Richard I ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Behavior; Benzodiazepine; CPP; Dizocilpine; GABA; Lorazepam; NMDA antagonist; Open field activity; Pentylenetetrazol induced seizures

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; DIZOCILPINE; LORAZEPAM; PENTETRAZOLE;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

ANIMALS; DIZOCILPINE MALEATE; DRUG ANTAGONISM; EXCITATORY AMINO ACID ANTAGONISTS; GABA MODULATORS; LORAZEPAM; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; PENTYLENETETRAZOLE; PIPERAZINES; RECEPTORS, N-METHYL-D-ASPARTATE; SEIZURES; STEREOTYPED BEHAVIOR;

EID: 0032929227     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00145-2     Document Type: Article

References (33)

1. Behrens S., Gattaz W.F. MK-801 induced stereotypies in rats are decreased by haloperidol and increased by diazepam. J. Neural Transm. 90:1992;219-224.
2. Bhargava H.N. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome and self-administration behaviors. Pharmacol. Ref. 46:1994;293-324.
3. Bubser M., Keseberg U., Notz P.K., Schmidt W.J. Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur. J. Pharmacol. 229:1992;75-82.
4. Byrnes J.J., Miller L.G., Perkins K., Greenblatt D.J., Shader R.I. Chronic benzodiazepine administration XI. Concurrent administration of PK. 11195(attenuates lorazepam discontinuation effects. Neuropsychopharmacology 8):1993;267-273.
5. Chapman A.G., Meldrum B.S. Non-competitive N-methyl-d-aspartate antagonists protect against sound-induced seizures in DBA/2 mice. Eur. J. Pharmacol. 166:1989;201-211.
6. Chapman A.G., Meldrum B.S., Nanji N., Watkins J.C. Anticonvulsant action and biochemical effects in DBA/2 mice of CPP [3-((±)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate], a novel N-methyl-d-aspartate antagonist. Eur. J. Pharmacol. 139:1987;91-96.
7. Clineschmidt B.V., Martin G.E., Bunting P.R. Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-amine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolytic properties. Drug Dev. Res. 2:1982;123-134.
8. Corbett R., Dunn R.W. Effects of 5,7 dichlorokynurenic acid on conflict, social interaction and plus maze behaviors. Neuropharmacology. 32:1993;461-466.
9. Corda M.G., Orlandi M., Lecca D., Giorgi O. Decrease in GABAergic function induced by pentylenetetrazol kindling in rats. Antagonism by MK-801 J. Pharmacol. Exp. Ther. 262:1992;792-800.
10. Croucher M.J., Bradford H.F., Sunter D.C., Watkins J.C. Inhibition of the development of electrical kindling of the prepiriform cortex by daily focal injections of excitatory amino acid antagonists. Eur. J. Pharmacol. 152:1988;29-38.
11. Dai H., Gebhardt K., Carey R.J. Time course effects of MK-801. The relationship between brain neurochemistry and behavior Brain Res. Bull. 36:1995;175-180.
12. File S.E., Fernandes C. Dizocilpine prevents the development of tolerance to the sedative effects of diazepam in rats. Pharmacol. Biochem. Behav. 47:1994;823-826.
13. A-receptor function. Br. J. Pharmacol. 101:1990;839-842.
14. Hegarty A.A., Vogel W.H. The effect of acute and chronic diazepam treatment on stress-induced changes in cortical dopamine in the rat. Pharmacol. Biochem. Behav. 52:1995;771-778.
15. Herman B.H., Vocci F., Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Neuropsychopharmacology. 13:1995;269-293.
16. Kehne J.H., McCloskey T.C., Baron B.M., Chi E.M., Harrison B.L., Whitten J.P., Palfreyman M.G. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. Eur. J. Pharmacol. 193:1991;283-292.
17. Koff J.M., Pritchard G.A., Greenblatt D.J., Miller L.G. The NMDA receptor competitive antagonist CPP modulates benzodiazepine tolerance and discontinuation. Pharmacology. 55:1997;217-227.
18. Liljequist S., Ossowska K., Grabowska-Anden M., Anden N.E. Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur. J. Pharmacol. 195:1991;55-61.
19. Lopez F., Miller L.G., Greenblatt D.J., Paul S.M., Shader R.I. Low-dose alprazolam augments motor activity in mice. Pharmacol. Biochem. Behav. 30:1988;511-513.
20. Löscher W., Honack D. The behavioural effects of MK-801 in rats. Involvement of dopaminergic, serotonergic and noradrenergic systems Eur. J. Pharmacol. 215:1992;199-208.
21. Löscher W., Nolting B., Honack D. Evaluation of CPP, a selective NMDA antagonist, in various rodent models of epilepsy. Comparison with other NMDA antagonists, and with diazepam and epilepsy. Comparison with other NMDA antagonists, and with diazepam and phenobarbitol. Eur. J. Pharmacol. 152:1988;9-17.
22. McNamara J.O., Russel R.D., Rigsbee L., Bonhaus D.W. Anticonvulsant and antiepileptogenic actions of MK-801 in the kindling and electroshock models. Neuropharmacology. 27:1988;563-568.
23. A receptor binding and function associated with chronic benzodiazepine antagonist administration. J. Pharmacol. Exp. Therap. 248:1989;1096-1101.
24. Murai T., Koshikawa N., Kanayama T., Takada K., Tomiyama K., Kobayashi M. Opposite effects of midazolam and beta-carboline-3-carboxylate ethyl ester on the release of dopamine from rat nucleus accumbens measured by in vivo microdialysis. Eur. J. Pharmacol. 261:1994;65-71.
25. Pritchard G.A., Galpern W.R., Lumpkin M., Miller L.G. Chronic benzodiazepine administration VIII. Receptor upregulation produced by chronic exposure to the inverse agonist FG-7142. J. Pharmacol. Exp. Ther. 258:1991;280-285.
26. Ragozzino D., Eusebi F. Inhibition of GABA and glycine responses by glutamate in rat hippocampal neurons. Brain Res. 628:1993;115-120.
27. Schatzki A., Lopez F., Greenblatt D.J., Shader R.I., Miller L.G. Lorazepam discontinuation promotes "inverse agonist" effects of benzodiazepines. Br. J. Pharmacol. 98:1989;451-454.
28. Shader R.I., Fogelman S.M., Greenblatt D.J. Newer antidepressants. Further reflections J. Clin. Psychopharmacol. 17:1997;75-77.
29. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R. Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment. Implications for the pharmacotherapy of depression Pharmacopsychiatry. 29:1996;23-26.
30. A receptor function by N-methyl-d-aspartate-mediated calcium influx in isolated CA1 pyramidal cells. Neuroscience. 62:1994;813-828.
31. Steppuhn K.G., Turski L. Diazepam dependence prevented by glutamate antagonists. Proc. Natl. Acad. Sci. USA. 90:1993;6889-6893.
32. Svensson A., Pileblad E., Carlsson M. A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J. Neural Transm. 85:1991;117-129.
33. Wisden W., Seeburg P.H. Mammalian ionotropic glutamate receptors. Curr. Opin. Neurobiol. 3:1993;291-298.